Eigencluster: Presentation 1 notes

• Advisory Committee
  • Get the official titles of Jon Kaufman and Ira Haimowitz (CSO)

• Bioinformatics industry
  • why is it important that the info generated by biotech industry doubles every 6 months?
  • emphasize that if pharma has better data analysis, they can speed up drug trials by 33%
  • Who are the lead players and how much do they have?

• Clustering algorithms
  • What algorithms do our competitors use? This may be hard to find, but we should try.

• Niche opportunities
  • What part of the biotech market is SNP analysis software?
  • Why did we choose biotech?

• Customers
  • Who are our gold buyers?
  • Who are our first buyers? Academics?
  • Talk to potential buyers
    • How do they decide if it's worth doing a trial?
    • How do they go about buying a product? Do they have any regrets about their current products?
    • How often do they get servicing?
  • Problems with big pharma
    • It may take them a year longer to decide if they will use our product. What do we do in this case?
    • Accreditation time?
    • We might want to increase service fee so get more $$. Many companies make the bulk of their money through service.
  • To what extent is habit important?
  • Recent NCI/Illumina contract
    • How was this brokered?
    • How did the timing of sales work?
    • Was there a trial basis over which they look at several products and choose one?

• IP info
  • What is the track record of the inventor?
  • Is the product patented yet?
  • How many patents have been filed in this field in the past few years?

• Why not keep our algorithm to ourselves?
• How much money do we want right now?
• Financial projection
  • Bear in mind that revenue must be divided among 12 months. Sales in Q3 and Q4 only count 50% and 25% of sales.